Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DESOXYN | Key Therapeutics | N-005378 RX | 1982-01-01 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
methamphetamine hydrochloride | ANDA | 2024-12-10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Substance-related disorders | D019966 | EFO_0003890 | F13 | 14 | 19 | 3 | 3 | 25 | 60 |
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 8 | — | 2 | 10 | 20 |
Depression | D003863 | — | F33.9 | 1 | — | 1 | 3 | 4 | 9 |
Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | — | — | 3 | 4 | 8 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | — | 1 | 4 | 6 |
Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | 1 | 4 | 5 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | 2 | 3 |
Psychotic disorders | D011618 | — | F20.81 | — | — | — | 2 | 1 | 3 |
Problem behavior | D000066553 | — | — | — | — | — | 1 | 2 | 3 |
Recurrence | D012008 | — | — | — | 1 | — | 1 | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 1 | — | 2 | 4 |
Drug overdose | D062787 | — | — | — | 2 | 1 | — | 1 | 3 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | — | 1 |
Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | 1 | — | — | 1 |
Substance withdrawal syndrome | D013375 | EFO_0005800 | — | — | 1 | 1 | — | — | 1 |
Critical illness | D016638 | — | — | — | — | 1 | — | — | 1 |
Acute kidney injury | D058186 | — | N17 | — | — | 1 | — | — | 1 |
Pain management | D059408 | — | — | — | — | 1 | — | — | 1 |
Periodontal diseases | D010510 | — | K05.6 | — | 1 | 1 | — | — | 1 |
Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 11 | 13 | — | — | 14 | 36 |
Addictive behavior | D016739 | EFO_0004347 | — | 2 | 5 | — | — | 9 | 16 |
Hiv | D006678 | — | O98.7 | 2 | 4 | — | — | 8 | 12 |
Stroke | D020521 | EFO_0000712 | I63.9 | 2 | 1 | — | — | 5 | 7 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | 5 | 6 |
Sexually transmitted diseases | D012749 | — | A50-A64 | 1 | 2 | — | — | 1 | 4 |
Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 2 | — | — | 1 | 3 |
Hiv seropositivity | D006679 | — | — | — | 1 | — | — | 1 | 2 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | 1 | 2 |
Alcohol drinking | D000428 | EFO_0004329 | — | — | 1 | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dental caries | D003731 | EFO_0003819 | K02 | 2 | — | — | — | 16 | 18 |
Healthy volunteers/patients | — | — | — | 4 | — | — | — | 3 | 7 |
Root caries | D017213 | EFO_1001163 | — | 1 | — | — | — | 2 | 3 |
Dental restoration failure | D019232 | — | — | 1 | — | — | — | 1 | 2 |
Affect | D000339 | — | — | 1 | — | — | — | 1 | 2 |
Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
Second primary neoplasms | D016609 | — | — | 1 | — | — | — | — | 1 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
Rectal neoplasms | D012004 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Fatigue | D005221 | — | R53.83 | — | — | — | — | 4 | 4 |
Sleep wake disorders | D012893 | — | G47 | — | — | — | — | 4 | 4 |
Cocaine-related disorders | D019970 | — | F14 | — | — | — | — | 4 | 4 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 4 | 4 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 4 | 4 |
Parasomnias | D020447 | — | G47.5 | — | — | — | — | 3 | 3 |
Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 3 | 3 |
Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 3 | 3 |
Amblyopia | D000550 | — | H53.00 | — | — | — | — | 3 | 3 |
Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | — | 3 | 3 |
Drug common name | Methamphetamine |
INN | metamfetamine |
Description | Methamphetamine[note 1] (contracted from N-methylamphetamine) is a potent central nervous system (CNS) stimulant that is mainly used as a recreational drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder and obesity. Methamphetamine was discovered in 1893 and exists as two enantiomers: levo-methamphetamine and dextro-methamphetamine.[note 2] Methamphetamine properly refers to a specific chemical substance, the racemic free base, which is an equal mixture of levomethamphetamine and dextromethamphetamine in their pure amine forms, but the hydrochloride salt, commonly called crystal meth, is widely used. Methamphetamine is rarely prescribed over concerns involving human neurotoxicity and potential for recreational use as an aphrodisiac and euphoriant, among other concerns, as well as the availability of safer substitute drugs with comparable treatment efficacy such as Adderall and Vyvanse. Dextromethamphetamine is a stronger CNS stimulant than levomethamphetamine.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN[C@@H](C)Cc1ccccc1 |
PDB | — |
CAS-ID | 537-46-2 |
RxCUI | — |
ChEMBL ID | CHEMBL1201201 |
ChEBI ID | 6809 |
PubChem CID | 1206 |
DrugBank | DB01577 |
UNII ID | 44RAL3456C (ChemIDplus, GSRS) |